Article Text

SP0128 Is Therapeutic Drug Monitoring Useful? A Review of the Literature
  1. D. Mulleman
  1. Rheumatology, Université François Rabelais de Tours, Tours, France


Objectives 1) Outline the structure and the pharmacology of TNF inhibitors (full lenth monoclonal antibodies, Fc-TNFR fusion protein, PEGylated Fab) that are currently used

2) Discuss the dose-response relationship and the sources of pharmacokinetics and pharmacokinetic-pharmacodynamic variability

3) Focus on the effect of inflammation on pharmacokinetics of TNF inhibitors and the potential interest to adapt the dosage of TNF inhibitors according to the patient's disease activity

Denis Mulleman, M.D., Ph.D., is professor of rheumatology at the University of Tours. He is member of the CNRS research unit 7292 (team 1: “Antibodies, Fc receptors and clinical responses”). His main research interest is to characterize the concentration-response relationship of anti-TNF monoclonal antibodies and Fc-containing fusion proteins to help clinicians personalize drug administration (therapeutic drug monitoring).

Disclosure of Interest D. Mulleman Grant/Research support from: Abbott, Consultant for: MSD, Pfizer

DOI 10.1136/annrheumdis-2014-eular.6302

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.